Insights from colour-blind octopus help fight human sight loss

Translate to Spanish or other 102 languages!

Cuttlefish. Prof Shelby Temple

Mega Doctor News

- Advertisement -

Newswise — University of Bristol research into octopus vision has led to a quick and easy test that helps optometrists identify people who are at greater risk of macular degeneration, the leading cause of incurable sight loss.

The basis for this breakthrough was published in the latest issue of the Journal of Experimental Biology and describes new technology developed by lead researcher, Professor Shelby Temple, to measure how well octopus– which are colour-blind – could detect polarized light, an aspect of light that humans can’t readily see. Using this novel technology, the research team showed that octopus have the most sensitive polarization vision system of any animal tested to date. Subsequent research used the same technology in humans and led to the development of a novel medical device that assesses the risk factor for sight loss later in life.

Prof Shelby Temple, who holds honorary positions at the School of Biological Sciences, University of Bristol and the School of Optometry, Aston University, explained the impact of the team’s findings. He said: “We knew that octopus, like many marine species, could see patterns in polarized light much like we see colour, but we had no idea that they could do so when the light was only 2% polarized – that was an exciting surprise, but even more surprising was when we then tested humans and found that they were able to see polarization patterns when the light was only 24% polarized.

- Advertisement -

“Humans can perceive polarized because macular pigments in our eyes differentially absorb violet-blue light depending on its angle of polarization, an effect known as Haidinger’s brushes. It’s like a super sense most of us don’t even know we have, revealing a faint yellow bow-tie shape on the retina. The more of these pigments a person has, the better protected they are against sight-loss.

“By inventing a method to measure polarization vision in octopuses, we were able to use the core technology to develop a novel ophthalmic device that can quickly and easily screen people for low macular pigments, a strong risk factor for increased susceptibility to macular degeneration.”

Macular pigments are the body’s natural protection against damaging violet-blue light. This new testing approach enables optometrists to provide preventative advice to patients. Empowering patients to make simple lifestyle choices, like wearing sunglasses or eating more dark green and brightly coloured fruits and vegetables that can help them protect their sight through life.

Prof Temple said, “I am so happy this work has been published, as it was the foundation upon which we developed our exciting new technology for measuring macular pigments.”

- Advertisement -

Macular pigments are the carotenoids lutein, zeaxanthin and meso-zeaxanthin that we can only acquire from our diet. They provide long term protection to the retina and this helps prevent age-related macular degeneration by acting as antioxidants and by strongly absorbing the most damaging high energy visible (violet-blue) wavelengths (380-500 nm) of light that reach our retina. A challenge to the eye care industry is that it is not possible to determine someone’s macular pigment levels without measurement, and until now most techniques have been too time consuming, difficult, or expensive to become part of regular eye exams. The new technology developed by Prof Temple through his start-up company Azul Optics Ltd, enables rapid screening of macular pigment levels and can be used on patients from 5 -95 years of age. Prof Temple added: “We are all living longer and expecting to do more in our older age, so I hope this serendipitous invention will help empower people to do more to look after our eyes, so they don’t suffer from this devastating disease.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease.

FDA Authorizes First Wearable Device that Continuously Monitors Both Ketone Levels and Blood Sugar

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.
- Advertisement -